This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hagens Berman: Whistleblower Helps To Expose Alleged Illegal Amgen Marketing Scheme

Hagens Berman Sobol Shapiro LLP, a law firm dedicated to representing whistleblowers today announced that its client, Marshall S. Horwitz, M.D., Ph.D., of Seattle, Wash., played a key role in uncovering an illegal scheme allegedly organized by pharmaceutical giant Amgen (NASDAQ: AMGN), which led to $762 million in criminal and civil penalties levied by the U.S. Department of Justice.

In 2006 Horwitz alerted authorities to Amgen’s alleged manipulation of the scientific record regarding two of its blockbuster drugs, Aranesp and Neulasta. He recognized that this manipulation led to more prescriptions for off-label uses of these drugs, which resulted in enormous expenditures by federal Medicare and state Medicaid programs, according to court documents.

In early 2007 Horwitz filed suit under the federal False Claims Act’s qui tam provisions, which allow whistleblowers to pursue recoveries on the government’s behalf for funds wrongfully paid. These provisions also allow whistleblowers to receive a portion of the funds recovered as a reward.

“We are proud to have represented Dr. Horwitz in this case,” said Steve Berman, managing partner of Hagens Berman. “It takes an incredible amount of courage to step forward and speak the truth in instances like this.”

“Dr. Horwitz helped put a stop to a fraud that was costing taxpayers billions of dollars, while also improving safety in the use of Aranesp and Neulasta,” Berman added. “For example, many of Dr. Horwitz’s allegations centered on Aranesp used as an off-label treatment for so-called anemia of cancer. That use has been shown to be quite dangerous to oncology patients, and Dr. Horwitz’s suit put a spotlight on Amgen’s unlawful efforts to increase Aranesp prescriptions for this condition.”

Berman also credited the commitment of the United States Attorney’s Office for the Western District of Washington, particularly AUSAs Harold Malkin, Peter Winn, and Susan Loitz. “Those prosecutors committed themselves to pursuing Amgen for its indefensible conduct and were a fantastic team to work with,” said Berman.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs